About the Company
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FGEN News
Q4 2023 FibroGen Inc Earnings Call
David DeLucia; VP of Corporate FP&A and IR; FibroGen, Inc. John J. Hunter; Chief Scientific Officer; FibroGen, Inc. Juan Graham; Senior VP & CFO; FibroGen, Inc. Thane ...
FibroGen Appoints Deyaa Adib As CMO
FibroGen, Inc. (FGEN), a biotechnology firm, announced on Monday that it has appointed Deyaa Adib as chief medical officer with ...
FibroGen regains rights to anemia drug from AstraZeneca
Feb 26 (Reuters) - FibroGen Inc (FGEN.O), opens new tab said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca (AZN.L), opens new tab in the United States and ...
FibroGen: Q4 Earnings Snapshot
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — FibroGen Inc. (FGEN) on Monday reported a loss of $56.2 million in its fourth quarter. The San Francisco-based company said it had a loss of 57 cents ...
FibroGen, Inc.: FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development ...
FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript
FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript February 26, 2024 FibroGen, Inc. misses on earnings expectations. Reported EPS is $-0.57 EPS, expectations were $-0.42. FibroGen ...
FibroGen regains rights to anemia drug from AstraZeneca
(Reuters) -FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca in the United States and certain other territories after the companies agreed to ...
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology ...
FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript
Thank you for standing by and welcome to FibroGen's Fourth Quarter and Full Year 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's call is being recorded.
Loading the latest forecasts...